December 7th 2023
A recent study revealed vaginal progesterone offers no significant reduction in preterm birth risk for twin gestations, prompting reconsideration of its proposed efficacy.
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
15th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 11, 2024
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
4th Annual International Congress on the Future of Women’s Health™
View More
Reducing postpartum length of stay following vaginal or cesarean delivery
September 13th 2023A targeted, collaborative approach to reduce length of stay (LOS) after cesarean or vaginal delivery resulted in a significant and sustained decrease in mean postpartum LOS without compromising patient safety, according to a poster featured at the 2023 Society of OB/GYN Hospitalists Annual Clinical Meeting, held in Chicago, Illinois.
Read More
FDA approves Pfizer’s maternal vaccine to prevent RSV in infants
August 22nd 2023Approved for use at 32 weeks through 36 weeks gestation, Pfizer’s maternal respiratory syncytial vaccine (Abrysvo), is delivered through a single dose injection to the muscle, and is the first vaccine for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD because of RSV in infants (birth to 6 months).
Read More